Compare WDC & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WDC | VRTX |
|---|---|---|
| Founded | 1970 | 1989 |
| Country | United States | United States |
| Employees | N/A | 6400 |
| Industry | Electronic Components | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.7B | 135.6B |
| IPO Year | 2001 | 2006 |
| Metric | WDC | VRTX |
|---|---|---|
| Price | $341.71 | $526.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 32 |
| Target Price | ★ $668.50 | $571.46 |
| AVG Volume (30 Days) | ★ 6.7M | 1.1M |
| Earning Date | 10-22-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | 374.22 | ★ 836.54 |
| EPS | 4.63 | ★ 8.33 |
| Revenue | ★ $12,919,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $49.19 | $10.54 |
| Revenue Next Year | $37.24 | $9.74 |
| P/E Ratio | ★ $14.55 | $64.00 |
| Revenue Growth | 35.70 | ★ 46.20 |
| 52 Week Low | $121.85 | $403.16 |
| 52 Week High | $799.87 | $560.25 |
| Indicator | WDC | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.10 | 55.79 |
| Support Level | $332.43 | $493.75 |
| Resistance Level | $483.67 | $531.78 |
| Average True Range (ATR) | 17.60 | 12.57 |
| MACD | -2.74 | 3.53 |
| Stochastic Oscillator | 10.11 | 77.83 |
Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).